Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for RAP-219 in Bipolar mania. The expected timing is based on the latest available company guidance and may change.
8/7/25- Trial initiated and enrollment is ongoing. Topline results in H1 2027. 11/06/25:- Ph2 bipolar mania proof-of-concept trial continues enrolling and remains on track for topline results in H1 2027. 03/10/26:- Phase 2 bipolar mania trial continues enrolling, remains on track for topline H1 2027; Tenacia licenses Greater China rights. 05/07/26:- Bipolar mania Ph2 topline now Q4 2026; enrollment strong, SAP updated, higher enrollment may provide confirmatory evidence. 08/05/26:- Ph2 topline results now expected October 2026; enrollment increased and SAP modified.
Verification
Confirm timing and program details against the company announcement or filing.